secondary amyloidosis

(redirected from AA amyloidosis)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to AA amyloidosis: AL amyloidosis, reactive amyloidosis

secondary amyloidosis

[′sek·ən‚der·ē ‚am·ə‚lȯi′dō·səs]
(medicine)
Amyloidosis that usually follows chronic suppurative, inflammatory diseases, such as tuberculosis, osteomyelitis, and bronchiectasis.
Mentioned in ?
References in periodicals archive ?
Therefore, negative light chain staining in association with amyloid does not rule out AL amyloidosis and may not be suggestive of AA amyloidosis in renal biopsies.
Natural history and outcome in systemic AA amyloidosis.
Additional injuries that may be related to the underlying neoplasm or its treatment regimen include TMA, AA amyloidosis, MN, IgAN, MPGN, pauci-immune crescentic GN, FSGS, minimal-change disease, acute interstitial nephritis, and xanthogranulomatous pyelonephritis.
Neurochem has also submitted for marketing approval eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis in the European Union and Switzerland.
The Company also filed for marketing approval for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis in Switzerland.
Our treatment approach, up to this point, has been limited to controlling the inflammatory condition that underlies the development of AA amyloidosis.
The data that emerged from the Phase II/III clinical trial is indicative of the product candidate's consistent benefit on slowing the decline in kidney function associated with AA amyloidosis.
Kiacta has shown promising efficacy in the systemic inflammatory disease AA amyloidosis, and we are pleased to have the opportunity to assess it as a potential therapy for sarcoidosis, an orphan indication that has few current treatment options.
Increasing fatal AA amyloidosis in hunting falcons and how to identify the risk: a report from the United Arab Emirates.
Most of our AA amyloidosis cases were classified as classes II, III, and IV, in which glomerular amyloid deposits were more commonly associated with the arteriolar walls.
Colchicine treatment of AA amyloidosis of familial Mediterranean fever.
KIACTA(TM) is being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis.